Tg Therapeutics' 15min chart shows MACD Death Cross and KDJ Death Cross.

Tg Therapeutics's 15-minute chart has recently exhibited a MACD Death Cross and KDJ Death Cross on August 8, 2025 at 14:15. This trend reversal suggests that the stock price has the potential to continue declining, as momentum shifts towards the downside and may lead to further decreases in value.

Tg Therapeutics (TGTX) has recently experienced a significant shift in its stock price momentum, as indicated by a MACD Death Cross and KDJ Death Cross on its 15-minute chart. These technical indicators emerged on August 8, 2025, at 14:15, signaling a potential downward trend in the stock price. The MACD Death Cross, a reversal pattern, occurs when the MACD line crosses below the signal line, indicating a potential trend reversal [1]. The KDJ Death Cross, another reversal pattern, occurs when the K-line crosses below the J-line on the KDJ indicator, signaling a potential trend reversal [2]. These patterns suggest that the momentum of the stock price is shifting towards the downside, with sellers currently dominating the market.

The emergence of these bearish signals on TGTX's 15-minute chart is not an isolated incident. Similar patterns have been observed in other stocks, such as Univest Financial and Telix, which have shown similar bearish signals [3][4]. Investors should closely monitor Tg Therapeutics for further signs of downward trends.

In addition to the technical indicators, Tg Therapeutics recently reported its second-quarter earnings, which were mixed. The company reported earnings of 17 cents per share, substantially missing the Zacks Consensus Estimate of 32 cents. Revenues in the second quarter totaled $141.1 million, up almost 92% year over year, driven by the strong demand for the company’s sole marketed drug, Briumvi (ublituximab-xiiy) [5]. Despite raising its revenue outlook for Briumvi to $570-$575 million, the figure fell short of analysts' expectations of $596 million. Additionally, the company increased its total global revenue target to $585 million for 2025 [6].

The recent technical analysis and earnings report suggest that investors should be cautious about Tg Therapeutics stock. The bearish momentum indicated by the MACD Death Cross and KDJ Death Cross, along with the mixed earnings announcement, may signal further potential declines in the stock price.

References:
[1] https://www.ainvest.com/news/trip-15-minute-chart-triggers-kdj-death-cross-bearish-marubozu-2508/
[2] https://www.ainvest.com/news/eagle-financial-15min-chart-triggers-kdj-death-cross-bearish-marubozu-signal-2507/
[3] https://www.ainvest.com/news/telix-15min-chart-triggers-kdj-death-cross-bearish-marubozu-pattern-2507/
[4] https://www.ainvest.com/news/univest-financial-15min-chart-triggers-macd-death-cross-bearish-marubozu-candle-2508/
[5] https://www.barchart.com/story/news/33894778/tgtx-down-as-q2-earnings-miss-mark-briumvi-sales-drive-top-line
[6] https://www.inkl.com/news/briumvi-s-strong-sales-can-t-stop-tg-therapeutics-stock-slide